Trial · NCT00289783
Trial comparisons27
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 20 of 27
Download this page as JSON| Comparison | Source |
|---|---|
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Increased Circumferential Swelling at the Injection Limb(s) | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects With Anti-measles Antibody Concentrations Equal to or Above 200 Milli-international Units Per Millilitre (mIU/mL) | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Unsolicited Adverse Events (AEs) | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Fever Above 39.5 Degrees Celsius/103.1 Degrees Fahrenheit | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects With hSBA-MenC Titer Equal to or Above 1:8 | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER) Visits | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects With Anti-varicella Titer Equal to or Above 1:40 | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Serious Adverse Events (SAEs) | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects With Anti-PRP Antibody Concentration Equal to or Above 1.0 Microgram Per Milliliter | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Serious Adverse Events (SAEs) | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects With hSBA-MenY Titer Equal to or Above 1:8 | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Unsolicited Adverse Events (AEs) | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects With Anti-rubella Antibody Concentrations Equal to or Above 10 International Units Per Milli-litre (IU/mL) | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting New Onset of Chronic Illness(es) (NOCDs) | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects With Anti-PRP Antibody Concentration Equal to or Above 1.0 Microgram Per Milliliter (µg/mL). | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Fever Above 39.5 Degrees Celsius/103.1 Degrees Fahrenheit | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Adverse Events Resulting in Physicians (MD) Office Visits | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects With Anti-mumps Titer Equal to or Above 28 Estimated Dose 50 (ED50) | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects With Anti-rubella Antibody Concentrations Equal to or Above 4 International Units Per Millilitre (IU/mL) | Trial comparisons |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Adverse Events Resulting in Physicians (MD) Office Visits. | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00289783/comparisons